LABRHA participated in the last OARSI Congress which took place from the 31st of March to the 3rd of April 2016 in Amsterdam. The company presented the results of the double-blind, controlled, multicenter, randomized trial conducted on 226 patients and comparing the efficacy and tolerance of HAppyVisc® vs. Euflexxa®. Read more…
Steroids, lidocaine and ioxaglic acid modify the viscosity of hyaluronic acid: in vitro study and clinical implications. T. Conrozier; J. Patarin; P. Mathieu; M. Rinaudo. SpringerPlus . 2016 Feb 24;5:170; doi: 10.1186/s40064-016-1762-z. During viscosupplementation, it is usual to inject other drugs, without knowing whether this association may have a deleterious Read more…
LABRHA participated in the 3rd International Symposium on Intra-Articular Treatment (ISIAT) Congress which took place in Budapest last 1-3 October 2015. The following 4 oral communications were presented for the company by Dr. Thierry Conrozier: Safety and efficacy of intra articular injections of a combination of hyaluronic acid and mannitol Read more…
LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. After the success of the 1st Edition last 22-23 May 2014, LABRHA has decided to continue the adventure and launch the 2nd Edition of the European Board on Viscosupplementation. This 2nd Edition Read more…
TOL19-001 reduces inflammation and MMP expression in monolayer cultures of tendon cells by C. Baugé et al. BMC Complementary and Alternative Medicine 2015; 15:217; doi 10.1186/s12906-015-0748-7. Abstract Background Tendinopathies are tendon conditions associated with degeneration and disorganization of the matrix collagen fibers, tendon cells apoptosis and inflammation through up-regulation of Read more…